Training Example: Codagenix – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H1] Engineering viruses to transform global health.

Codagenix is combining live-attenuated virus design with cutting-edge codon deoptimization technology for a powerful, synthetic biology-based platform poised to take on our biggest threats in infectious disease.

Scroll down

[IMG: Masked scientist analyzes liquid sample in a test tube in high tech lab]

Science
[H2] Leading the new era of live vaccines.

Leveraging a proprietary synthetic biology-driven approach that designs hundreds of precise, stable edits into a viral genome, Codagenix is delivering solutions for infectious disease that have all the broad immunity benefits of live-attenuated viruses combined with safety, speed and scalability.

Our Approach

[H2] In the News

[H3] Codagenix Awarded PATH Subcontract to Develop Stabilized Novel Oral Polio Vaccine Candidates

Read more

BioSpace

[H3] JPM2024: On the Ground in San Francisco

Read more

WSJ Pro Venture Capital

[H3] Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024

Read more

[H2] Work with us

We’re building a team of fearless pioneers to take on global health challenges.

Careers

[H1] Approach Precision is power.

Infectious Disease

Cancer Virotherapeutics

Animal Health

Scroll to

The Codagenix platform is revolutionizing the vaccine development process with a synthetic biology-enabled approach that eliminates guesswork in favor of precisely designed solutions.

[H2] Infectious Disease

The ultimate stable and broadly efficacious vaccine approach.
Trusted for decades to solve many of the world’s most pressing global health challenges, live-attenuated vaccines are the gold standard. Unlike other single antigen-focused approaches, including vectored and mRNA vaccines, live vaccines are readily deployable, often offer lifetime protection in just one or two doses, and safely mimic a natural infection to enable a broad immune response to the entire virus. Downsides of live vaccines have been exceedingly long timelines for development, including testing for the right amount of attenuation, and genetic instability.
Our codon deoptimized live vaccine candidates overcome these drawbacks,
delivering all the benefits of live vaccines on short timelines and with unparalleled genetic stability.

[H2] Known benefits of live-attenuated vaccines

Mimic the protection from natural infection without causing disease

Broad immunity to all viral antigens

Both B and T cell immunity

Durable immune memory response that may not require booster

Readily scalable

[IMG: Scientist uses computer to aid research.]

[IMG: Woman and her son wear masks while grocery shopping.]

[H2] Live vaccines meet software-enabled codon deoptimization.
Codagenix is pushing this proven approach into the clinic and beyond by merging live-attenuated viruses with a novel codon deoptimization approach that leverages cutting-edge developments in synthetic biology and machine learning.
Our “death by a thousand cuts” approach takes the genetic sequence of the wild-type target and uses machine learning to compute the hundreds or thousands of sites where codons can be modified to produce the same amino acid sequence with lower translational efficiency. This process yields a small, testable number of candidate viral genomes that produce all the same proteins as the wild type but with far less virulence, significantly accelerating timelines for candidate development.
Unlike traditional live vaccines, which contain only a small number of mutations, our codon deoptimized vaccines contain hundreds of intentionally placed edits, making it probabilistically impossible for the virus to revert to the wild-type phenotype.
[H2] Stable in vitro manufacturing, safe in vivo immunity.
Codagenix leverages decades-proven manufacturing for our vaccine and therapeutics. Our live-attenuated viruses can be effectively produced in cell culture which does not possess adaptive immunity at commercial scale in existing manufacturing facilities, stored in conventional cold chains and easily delivered to far reaches of the globe. They also have dose-sparing potential to accelerate the distribution of life-saving vaccines even further.

Addressing global challenges requires global collaboration. We are partnering with the World Health Organization and Serum Institute of India to develop, manufacture and deliver CoviLiv, our novel intranasal COVID-19 vaccine candidate, to places in need around the world.

[IMG: Smiling woman shakes hands with her doctor.]

[IMG: Two masked scientists in protective attire walk down a brightly lit laboratory corridor.]

[H2] Cancer Virotherapeutics

Turning up the heat on cold tumors.
Our virus engineering platform can also be applied to develop novel immunotherapies for cancer. We are building on oncolytic viruses as a proven modality with potential to broaden and deepen responses to immune checkpoint inhibitors and other combination partners.
Designing viruses that put the patient first.
Codon pair modification allows us to ensure our virotherapeutics retain the exceptional safety profiles of oncolytic viruses observed across virus species. Recoded viral genomes provide a potent layer of tumor cell specificity, since viral replication is simultaneously sustained in tumor cells with defective innate immune sensing mechanisms and restricted in healthy cells.
In addition, the species-agnostic nature of the synthetic engineering platform allows us to choose the optimal virus for a tumor type based on receptor expression. This means that rather than a single oncolytic virus searching for a clinical indication, the Codagenix discovery platform is designed to identify novel virotherapeutics customized to a specific cancer type.

[H2] Virotherapeutics fit for purpose.
Codagenix’s virotherapeutics harness the natural ability of selected viruses to induce potent innate and adaptive immune responses. This modulates the tumor microenvironment in multiple ways, favoring anti-tumor immune responses.

Codagenix virotherapeutics offer a path toward more powerful cancer therapies, both kick-starting the cancer immunity cycle and working synergistically with other cancer modalities for greater clinical benefit.

[H2] Animal Health

Stronger global health through healthier animals.
Healthy animals are fundamental to the health of people and our planet through companionship, high-quality nutrition and the control of zoonotic diseases. Codagenix is pioneering the next generation of animal health vaccines and virotherapeutics at a time when new innovations are critical—to strengthen our food chain, make pets healthier, and lower our global reliance on antibiotics.

[IMG: Woman feeds cattle and livestock on a farm.]
Livestock Infectious disease remains a significant cause of lost agricultural production. Codagenix’s innovative platform can reduce these losses through targeted vaccination against both viral and bacterial infections, as well as empower the agricultural community to reduce antibiotic use in production animals.

[IMG: Man pets his companion animal.]
Companion Animals Better medical care for our pets has already led to longer lifespans and happier animals. Codagenix’s platform can provide better vaccines for common as well as emerging diseases, increasing healthy life years and improving quality of life for animals and owners alike.

[H2] Track our progress

Learn more about our next-generation platform.

Our pipeline

[H1] Careers Join the Codagenix team.

Codagenix is expanding the reach of our platform to solve pressing needs in global health. We are looking for passionate people to bring creativity and drive to our mission of preventing infectious disease, treating cancer, improving animal health, and more.

[IMG: Two scientists in lab coats discuss research in laboratory.]

[IMG: Scientist in goggles smiles while operating instrumentation.]

[H2] Openings

[H1] Pipeline Faster, better viral vaccines and therapeutics.

Infectious Disease

Cancer Virotherapeutics

Animal Health

Scroll to

Our pipeline produces vaccine and viral therapeutic candidates capable of rapidly and specifically responding to our most pressing global health threats.

[H2] Infectious Disease

Our platform makes trial-and-error vaccine development a thing of the past.
Codagenix designs and develops several vaccine candidates in tandem, enabling us to go from genetic sequence of the wild-type virus to viable candidate vaccine or therapeutic in weeks—and faster, if needed, as new outbreak strains are identified.

Program
Pre-clinicalPreclinical
Phase 1
Phase 2
Phase 3
Dengue
CDX-DENV

Dengue is a mosquito-borne viral infection that is common in warm, tropical climates. Globally, approximately 2.5 billion people live in dengue-endemic regions. Vaccine development has been challenging as protection against all four dengue virus serotypes is required to avoiding antibody-mediated enhancement of disease. Additionally, current dengue vaccines in development are designed using traditional vectored or serial passage approaches of the historical dengue strain.
Codagenix has leveraged its platform to re-design fully-homologous, contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates.
RSV CodaVaxTM – RSV
Adult

Pediatric

Respiratory syncytial virus (RSV) is a leading cause of hospitalization due to acute lower respiratory infection, particularly in infants, young children and elderly adults.
Overcoming long-standing hurdles, our intranasal RSV candidate is genetically stable, induces a meaningful T cell response and is efficacious against wild type challenge in primates. A Phase 1 clinical trial in healthy adults reached its primary endpoint, demonstrating both safety and an anti-RSV cellular immune response. A Phase 1 clinical trial in toddlers and infants is ongoing.

Influenza
Pandemic

Influenza carries a year-round disease burden and can cause severe illness or death, particularly among high-risk populations. The current major vaccines are focused on an antibody response to the highly variable HA protein of influenza.
Codagenix is developing platform designs to address intranasal, pan-type A live-attenuated virus vaccines. Our prototype design, CodaVax™-H1N1, has demonstrated cross-protection in accepted animal models, even against HPAI H5N1. We are currently developing a next-generation platform design that supports rapid swapping of highly variable surface antigens.

Polio (nOPV)

Surveillance during the global rollout of >1 billion doses of nOPV2 has continued to support, during outbreak response, the enhanced genetic stability that was demonstrated in preclinical and clinical testing of this innovative vaccine, when compared to traditional Sabin oral polio vaccine type 2 (OPV2) use. While this has importantly included an estimated 80% reduction in the emergence of new type 2 circulating vaccine-derived PV (cVDPV2) emergences, it has also revealed that nOPV2 does retain a residual capacity to recombine with close genetic relatives, including Sabin strains and C-cluster non-polio enteroviruses (NPEV-C).
Codagenix is applying its proprietary synthetic biology technology to modify novel oral poliovirus vaccine (nOPV) strains making them less prone to recombination with other enteroviruses and reducing the risk to cause disease or transmission.
SARS-CoV-2 (COVID-19)
CoviLivTM

The COVID-19 pandemic has impacted countless lives and caused millions of deaths worldwide.
Our intranasal vaccine candidate CoviLiv is a live-attenuated vaccine, safely enabling a broad antibody and T-cell response.

Yellow Fever

Yellow fever is a viral disease transmitted to humans through bites of infected mosquitoes. The current vaccine is in short or absent supply and relies on antiquated egg-based production. With the habitat of the mosquito vectors expanding into previously temperate latitudes, this disease represents a growing threat to global health.
We have synthesized the vaccine strain and are testing it in vivo to support candidate selection, ultimately aiming for a clinical program utilizing an FDA-accepted surrogate endpoint for registration to allow for accelerated clinical development.
Zika
CDX-ZiKV

Zika virus is primarily transmitted by the bite of an infected mosquito, and can also be transmitted through other contacts, including from mother to fetus during pregnancy. This transmission is associated with microencephaly in infants. To date, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.
Codagenix has leveraged our platform to re-design the Zika vaccine and demonstrate a product that is safe and immunogenic in primates.

[H2] Cancer Virotherapeutics

Shifting the long-standing trajectory of cancer immunotherapies.
Our influenza-based virotherapeutic candidate is the first codon-modified attenuated virus developed to treat cancer.

Program
Pre-clinicalPreclinical
Phase 1
Phase 2
Phase 3

Breast Cancer
CodaLyticTM

Breast cancer is one of the leading contributors to cancer-related death worldwide, but remains difficult to target with existing immunotherapies due in part to heterogeneity between breast cancer subtypes and unfavorable tumor microenvironments. Particularly in later stage metastatic settings, there is great unmet need for novel therapy regimens to improve patient outcomes.
Our lead candidate is designed to modulate the tumor microenvironment in multiple ways, leading to reliable anti-tumor efficacy in immune-competent mouse models of breast cancer and triggering several immune effector mechanisms. IND-enabling studies are ongoing.
Solid Tumors
CDX-Onc

A variety of solid tumors can benefit from treatment with immunostimulatory viruses, broadening and deepening the patient population benefiting from established immunotherapies. We are actively discovering novel virotherapeutics by leveraging our platform to construct target-specific therapies, focusing on immunologically cold tumors.

[H2] Animal Health

The next generation of healthy animals.
Animals are fundamental to the health of people through companionship, high quality nutrition and the control of zoonotic diseases. Codagenix vaccines for agriculture and companion animals will strengthen our food chain, make pets healthier and lower our global reliance on antibiotics.

Area
INDICATION / PARTNER
Proof of concept
CLINICAL DEVELOPMENT
REGULATORY
MARKET AUTHORIZATION

Companion Animal
Canine
Not Public/Not Public

Farm Animal
Swine
Not Public/Not Public

Poultry
Not Public/Not Public

Swine
FMDV/USDA

Cattle
FMDV/USDA

For expanded access, visit our Expanded Access Policy